key: cord-0735582-1jpzlrf0
authors: SoRelle, J.; Mahimmainathan, L.; McCormick-Baw, C.; Cavuoti, D.; Lee, F.; Bararia, A.; Thomas, A.; Sarode, R.; Clark, A. E.; Muthukumar, A.
title: Evaluation of symptomatic patient saliva as a sample type for the Abbott ID NOW COVID-19 assay
date: 2020-06-03
journal: nan
DOI: 10.1101/2020.06.01.20119198
sha: f1c7ceaf32f7027f75e563795255ef8a47345cd4
doc_id: 735582
cord_uid: 1jpzlrf0

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has presented significant challenges for laboratories including supply chain limitations with restricted access to reagents and sample collection materials (i.e. swabs, viral transport media (VTM)) for patients testing. Therefore, saliva has been evaluated as an alternative specimen for COVID-19 diagnosis. comparable performance between dry nasal swabs (NS) and nasopharyngeal swabs (NPS) collected in VTM has been observed with the ID NOW for SARS-CoV-2; the majority of false-negative results occur with higher cycle number (CN) or cycle threshold (Ct) values suggesting low viral load in these specimens. We performed clinical validation of saliva specimens on the ID NOW molecular platform to detect SARS-CoV-2. Saliva was compared to nasopharyngeal swabs tested on the ID NOW and the Cepheid molecular assay. We also performed stability studies of saliva samples over 5 days. A total of 96 saliva samples and 64 paired NPS were analyzed. We observed 78% (18/23) positive percent agreement (PPA) and 100% (44/44) negative percent agreement (NPA) between matched saliva and nasopharyngeal specimens performed on ID NOW. We found 83% (19/23) PPA and 100% NPA (25/25) between saliva run on the ID NOW and Cepheid assay. Six saliva specimens positive for SARS-CoV-2 were continuously positive for five days when stored at room temperature. Therefore, we propose further investigation of saliva as an alternative sample type for testing symptomatic patients with ID NOW as a promising method to address COVID-19 testing.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has 23 presented significant challenges for laboratories including supply chain limitations with restricted 24 access to reagents and sample collection materials (i.e. swabs, viral transport media (VTM)) for 25 patients testing. Therefore, saliva has been evaluated as an alternative specimen for diagnosis. The collection of the saliva specimen does not require specialized materials, is non-27 invasive, and can be self-collected (1, 2). 28

Access to rapid and accurate testing is essential to limit the SARS-CoV-2 community 29 spread and curtail COVID-19 resurgence. The Abbott ID NOW (ID NOW, Abbott Diagnostics, 30 Sarborough, ME) is a point-of-care (POC) isothermal amplification-based platform that detects 31 SARS-CoV-2 from patient specimens in approximately five minutes. ID NOW is currently used in 32 pharmacies, hospitals, and various outpatient settings in all 50 states, and has a production 33 capacity of 2 million tests per month by June 2020 (3). 34

Recently, concerns regarding ID NOW sensitivity compared to RT-PCR assays have been 35 raised during clinical validations (4-7). The manufacturer has updated the specimen types 36 indicated for use and the product information directing confirmatory testing with another 37 molecular assay in cases of negative results with high clinical suspicion for COVID-19 (8). The 38 comparable performance between dry nasal swabs (NS) and nasopharyngeal swabs (NPS) 39 collected in VTM has been observed with the ID NOW for SARS-CoV-2 (4); the majority of false-40 negative results occur with higher cycle number (CN) or cycle threshold (Ct) values suggesting 41 low viral load in these specimens (5, 7). 42

In the setting of limited specimen collection resources and an unknown optimal sample 43 type for POC testing, we examined the performance of the ID NOW COVID-19 assay using 44 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.06.01.20119198 doi: medRxiv preprint symptomatic patient saliva. We tested a total of 96 patient saliva samples on the ID NOW. Sixty-45 seven specimens were paired collections with NPS in VTM. We first compared IDNOW saliva 46 results with results from paired NPS specimens tested by either the Xpert® Xpress SARS-CoV-2 47 (Cepheid, Sunnyvale, CA) or Real-Time SARS-CoV-2 (Abbott Molecular, Des Plaines, IL) RT-PCR 48 assays. All testing was performed per manufacturer's instructions, with 200µL of saliva being 49 used for ID NOW testing. 50

The limit of detection for the ID NOW was verified at 2000 copies/mL using synthetic RNA 51 (SARS-CoV-2 standard, Exact Diagnostics, Ft. Worth, TX), consistent with previously published 52 reports (7). We found a 78% (18/23) positive percent agreement (PPA) and 100% (43/43) 53 negative percent agreement (NPA) for saliva tested by ID NOW compared with NPS in VTM (Table  54 1). False-negative (FN) saliva samples were associated with elevated NPS CN (Abbott, N2: 30.44) 55 or Ct values (Cepheid, E: 33.0, 36.5, 40.6, 43.3; N2: 35.9, 36.1, 38.5, 39.0), consistent with 56 previous reports for NPS (7) . 57

We recently validated the Cepheid assay for use with saliva (9) and compared the 58 performance of ID NOW using 49 saliva specimens ( work revealed a majority (n=4/7, 2 were common) were tested >2 weeks after symptom onset, 62 with most already receiving a diagnosis of COVID-19. Three of the FN patients had a previous 63 diagnosis of COVID-19, another was diagnosed by ID NOW on an NPS specimen and retested 64 while in the hospital, one was de-identified with no information and the last had no previous 65 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.06.01.20119198 doi: medRxiv preprint diagnosis but had an atypical presentation of weakness, and diarrhea for two weeks with subtle 66 hazy opacities of the lung base indicative of minor respiratory disease. 67

Stability studies were undertaken to evaluate ID NOW performance as specimens aged 68 (i.e. conditions simulating self-collection). NPS has exhibited reliable SARS-CoV-2 stability over a 69 range of times and temperatures in a variety of storage media (10), but studies examining saliva 70 are lacking. Six SARS-CoV-2-positive saliva specimens were evaluated by the ID NOW daily over 71 5-days post-collection stored at room temperature (22-25°C). All specimens were found to 72 remain positive during serial testing with 200µL volumes over that time . 73

Resurgence in COVID-19 cases as social distancing and travel restrictions are relaxed 74 necessitate expanded accessibility to POC devices. Saliva utilization for ID NOW testing supports 75 self-collection and facilitates retesting of invalid or questionable results without the need for the 76 recollection of a second NS or NPS due to specimen exhaustion. This could also limit the exposure 77 of medical staff to potentially infectious patients. Therefore, we propose further investigation of 78 saliva as an alternative sample type for testing symptomatic patients with ID NOW as a promising 79 method to address COVID-19 testing. Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens. 87 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-88 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.06.01.20119198 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.06.01.20119198 doi: medRxiv preprint

fda-authorizes-first-diagnostic-test-using-home-collection-saliva

Saliva-Friend and Foe in the COVID-19 Outbreak

An update on Abbott's work on COVID-19 testing

Performance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test in 97 nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City 98 academic institution

Comparison of two commercial 101 molecular tests and a laboratory-developed modification of the CDC 2019-nCoV RT-PCR 102 assay for the detection of SARS-CoV-2

To-Answer Platforms for the Detection of SARS-CoV-2

108 Comparison of Abbott ID Now and Abbott m2000 methods for the detection of SARS-CoV-109 2 from nasopharyngeal and nasal swabs from symptomatic patients

Reducing risk by diagnosing with reliable point-of-care testing

Cavuoti 115 D. 2020. Saliva as an Alternate Specimen Source for Detection of SARS-CoV-2 in 116

Symptomatic Patients Using Cepheid Xpert Xpress SARS-CoV-2

Evaluation of Transport Media and Specimen Transport Conditions for the 120 Detection of SARS-CoV-2 Using Real Time Reverse Transcription PCR